TNF-alpha antagonists, infliximab (INF), etanercept (ETA) and adalimumab (ADA), have been demonstrated to be effective in controlling symptoms in SpAs. The aim of this study was to investigate the possibility of using ADA as a second or third choice.
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study / Spadaro, Antonio; Punzi, Leonardo; Marchesoni, Antonio; Lubrano, Ennio; Mathieu, Alessandro; Cantini, Fabrizio; Olivieri, Ignazio; Salvarani, Carlo; Scarpa, Raffaele; Scrivo, Rossana; Ramonda, Roberta; Porru, Giovanni; D'Angelo, Salvatore; Catanoso, Mariagrazia; Atteno, Mariangela; Valesini, Guido. - In: RHEUMATOLOGY. - ISSN 1462-0332. - 49:(2010), pp. 1107-1111. [10.1093/rheumatology/keq008]
Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study
SALVARANI, CARLO;
2010
Abstract
TNF-alpha antagonists, infliximab (INF), etanercept (ETA) and adalimumab (ADA), have been demonstrated to be effective in controlling symptoms in SpAs. The aim of this study was to investigate the possibility of using ADA as a second or third choice.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
